- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06260722
Effekt av Retatrutide sammenlignet med Semaglutid hos voksne deltakere med type 2-diabetes og utilstrekkelig glykemisk kontroll med metformin med eller uten SGLT2-hemmer (TRANSCEND-T2D-2)
En fase 3, randomisert, multisenter, åpen studie for å undersøke effektiviteten og sikkerheten til Retatrutide én gang i uken sammenlignet med Semaglutid én gang i uken hos voksne deltakere med type 2-diabetes og utilstrekkelig glykemisk kontroll med metformin med eller uten SGLT2-hemmer (TRANSCEND-T2D- 2)
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Buenos Aires, Argentina, C1056ABI
- Centro de Investigaciones Metabólicas (CINME)
-
Buenos Aires, Argentina, C1426ABP
- Fundación Respirar
-
Córdoba, Argentina, 5000
- Centro Diabetológico Dr. Waitman
-
-
Buenos Aires
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 1414
- CARE - Centro de Alergia y Enfermedades Respiratorias
-
-
Buenos Aires F.D.
-
Buenos Aires, Buenos Aires F.D., Argentina, C1425AGC
- Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
-
Buenos Aires, Buenos Aires F.D., Argentina, C1061AAS
- CIPREC
-
Buenos Aires, Buenos Aires F.D., Argentina, C1023AAB
- Stat Research S.A.
-
Buenos Aires, Buenos Aires F.D., Argentina, C1120AAC
- Centro Médico Viamonte
-
Buenos Aires, Buenos Aires F.D., Argentina, C1128AAF
- Mautalen Salud e Investigación
-
C.a.b.a., Buenos Aires F.D., Argentina, C1205AAO
- CEMEDIAB
-
CABA, Buenos Aires F.D., Argentina, 1204
- Instituto Centenario
-
-
Córdoba Province
-
Córdoba, Córdoba Province, Argentina, 5006
- Centro Medico Privado San Vicente Diabetes
-
-
Mendoza Province
-
Godoy Cruz, Mendoza Province, Argentina, 5501
- CIPADI - Centro Integral de Prevencion y Atencion en Diabetes
-
-
Santa Fe Province
-
Granadero Baigorria, Santa Fe Province, Argentina, 2152
- Centro de Investigaciones Clínicas Baigorria
-
Rosario, Santa Fe Province, Argentina, S2000CVD
- Instituto de Investigaciones Clinicas Rosario
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2T 5C7
- University of Calgary - Clinical Trials Unit
-
Edmonton, Alberta, Canada, T6G 2E1
- Alberta Diabetes Institute
-
-
Ontario
-
Brampton, Ontario, Canada, L6T 0G1
- Aggarwal and Associates Limited
-
Brampton, Ontario, Canada, L6S 0C6
- Centricity Research Brampton Endocrinology
-
Hamilton, Ontario, Canada, L8J 0B6
- Winterberry Research Inc.
-
Hamilton, Ontario, Canada, L8L 5G8
- The Wharton Medical Clinic Clinical Trials Inc
-
Hamilton, Ontario, Canada, L8L5G4
- Hamilton Medical Research Group
-
Sarnia, Ontario, Canada, N7T 4X3
- Bluewater Clinical Research Group Inc.
-
Toronto, Ontario, Canada, M4S 1Y2
- Prime Health Clinical Research
-
Toronto, Ontario, Canada, M5G 1K2
- Maple Leaf Research
-
Whitby, Ontario, Canada, L1N 2L1
- Private Practice - Dr. Nigel Jagan
-
-
Quebec
-
Montreal, Quebec, Canada, H4N 2W2
- 9109-0126 Quebec Inc.
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35294
- University of Alabama - Department of Nutrition Sciences
-
-
California
-
Escondido, California, Forente stater, 92025
- Neighborhood Healthcare Institute of Health
-
Long Beach, California, Forente stater, 90805
- Long Beach Research Institute
-
Northridge, California, Forente stater, 91325
- Valley Clinical Trials, Inc.
-
Rancho Cucamonga, California, Forente stater, 91730
- Rancho Cucamonga Clinical Research
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- University of Colorado Anschutz Medical Campus
-
-
Florida
-
Daytona Beach, Florida, Forente stater, 32117
- Arrow Clinical Trials
-
Miami, Florida, Forente stater, 33186
- New Age Medical Research Corporation
-
Miramar, Florida, Forente stater, 33027
- South Broward Research
-
Winter Haven, Florida, Forente stater, 33880
- Clinical Research of Central Florida
-
-
Georgia
-
Suwanee, Georgia, Forente stater, 30024
- Herman Clinical Research
-
Woodstock, Georgia, Forente stater, 30189
- North Georgia Clinical Research
-
-
Hawaii
-
Honolulu, Hawaii, Forente stater, 96817
- Pacific Diabetes & Endocrine Center
-
-
Idaho
-
Idaho Falls, Idaho, Forente stater, 83404
- Rocky Mountain Clinical Research
-
-
Indiana
-
Newburgh, Indiana, Forente stater, 47630
- Deaconess Clinic - Gateway Health Center
-
-
Louisiana
-
Monroe, Louisiana, Forente stater, 71201
- IMA Clinical Research Monroe - Armand
-
-
Maryland
-
Hyattsville, Maryland, Forente stater, 20782
- MedStar Health Research Institute (MedStar Physician Based Research Network)
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Brigham and Women's Hospital Diabetes Program
-
Fall River, Massachusetts, Forente stater, 02721
- NECCR PrimaCare Research
-
-
Michigan
-
Troy, Michigan, Forente stater, 48098
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89148
- Palm Research Center Sunset
-
Las Vegas, Nevada, Forente stater, 89128
- Palm Research Center Tenaya
-
-
New York
-
Long Island City, New York, Forente stater, 11106
- NYC Research INC
-
-
North Carolina
-
Greensboro, North Carolina, Forente stater, 27405
- Medication Management
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43215
- Remington Davis Clinical Research
-
-
Oklahoma
-
Norman, Oklahoma, Forente stater, 73069
- Alliance for Multispecialty Research, LLC
-
Tulsa, Oklahoma, Forente stater, 74136
- Central States Research
-
-
Oregon
-
Corvallis, Oregon, Forente stater, 97330
- The Corvallis Clinic, P.C.
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Thomas Jefferson University Hospital
-
-
Texas
-
Dallas, Texas, Forente stater, 75230
- Velocity Clinical Research, Dallas
-
Fort Worth, Texas, Forente stater, 76164
- Valley Institute of Research - Fort Worth
-
Houston, Texas, Forente stater, 77040
- Juno Research
-
Mesquite, Texas, Forente stater, 75149
- Southern Endocrinology Associates
-
Shavano Park, Texas, Forente stater, 78231
- Consano Clinical Research, LLC
-
Weslaco, Texas, Forente stater, 78596
- Texas Valley Clinical Research
-
Wylie, Texas, Forente stater, 75098
- Medrasa Clinical Research
-
-
Washington
-
Wenatchee, Washington, Forente stater, 98801
- Central Washington Health Services Association d/b/a Confluence Health
-
-
West Virginia
-
Morgantown, West Virginia, Forente stater, 26505
- IMA Clinical Research West Virginia
-
-
-
-
-
Chihuahua City, Mexico, 31110
- Enclifar Ensayos Clínicos Farmacológicos Sc
-
Veracruz, Mexico, 91851
- Instituto Veracruzano en Investigación Clínica S.C.
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44130
- Diseno y Planeacion en Investigacion Medica
-
-
Mexico City
-
Mexico City, Mexico City, Mexico, 11650
- Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares
-
Mexico City, Mexico City, Mexico, 03100
- RM Pharma Specialists
-
Mexico City, Mexico City, Mexico, 06090
- Hospital de Jésus, I.A.P.
-
-
Morelos
-
Cuernavaca, Morelos, Mexico, 62250
- Instituto de Diabetes, Obesidad y Nutricion
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 66460
- Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
-
Monterrey, Nuevo León, Mexico, 64610
- Clínica García Flores SC
-
Monterrey, Nuevo León, Mexico, 64060
- Cardiolink Clin Trials
-
-
-
-
-
Bayamón, Puerto Rico, 00959
- Advanced Clinical Research, LLC
-
San Juan, Puerto Rico, 00917
- GCM Medical Group, PSC - Hato Rey Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Have Type 2 Diabetes (T2D)
- Have HbA1c ≥ 7.0% (53 millimoles per mole (mmol/mol)) to ≤ 10.5% (91 mmol/mol)
- Have been on a stable diabetes treatment consisting of metformin ≥ 1500 milligrams per day (mg/day) with or without SGLT2i during 90 days prior to screening
- Are of stable weight for at least 90 days prior to screening
- Have a Body Mass Index (BMI) ≥ 25.0 kilograms per meter squared (kg/m^2)
Exclusion Criteria:
- Have Type 1 Diabetes (T1D)
- Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening
- Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening
- Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
- Have an estimated glomerular filtration rate (eGFR) <45 milliliters/minute/1.73 meter squared (mL/min/1.73 m^2) or lower than the country-specific threshold for discontinuing metformin therapy per local label as determined by the central laboratory
- Have a prior or planned surgical treatment for obesity
- Have New York Heart Association Functional Classification IV congestive heart failure
- Have had an acute myocardial infarction, stroke, or were hospitalized for congestive heart failure within 90 days prior to screening
- Have a known clinically significant gastric emptying abnormality
- Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years
- Have any lifetime history of a suicide attempt
- Had chronic or acute pancreatitis
- Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2
- Have taken prescribed or over-the-counter medication, or alternative remedies, intended to promote body weight reduction within 90 days prior to screening.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Retatrutide Dose Level 1
Participants will receive retatrutide administered subcutaneously (SC). |
Administered SC.
Andre navn:
|
|
Eksperimentell: Retatrutide Dose Level 2
Participants will receive retatrutide administered SC. |
Administered SC.
Andre navn:
|
|
Aktiv komparator: Semaglutide
Participants will receive semaglutide administered SC. |
Administered SC. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Endring fra baseline i hemoglobin A1c (HbA1c) (%)
Tidsramme: Grunnlinje, uke 80
|
Grunnlinje, uke 80
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Endring fra baseline i systolisk blodtrykk (SBP)
Tidsramme: Grunnlinje, uke 80
|
Grunnlinje, uke 80
|
|
Endring fra baseline i HbA1c (%)
Tidsramme: Grunnlinje, uke 80
|
Grunnlinje, uke 80
|
|
Prosentandel av deltakere som oppnår HbA1c ≤ 6,5 %
Tidsramme: Uke 80
|
Uke 80
|
|
Prosentandel av deltakere som oppnår HbA1c < 5,7 %
Tidsramme: Uke 80
|
Uke 80
|
|
Prosentvis endring fra baseline i kroppsvekt
Tidsramme: Uke 80
|
Uke 80
|
|
Endring fra baseline i kroppsvekt
Tidsramme: Grunnlinje, uke 80
|
Grunnlinje, uke 80
|
|
Prosentandel av deltakere som oppnår vektreduksjon på ≥ 5 %
Tidsramme: Uke 80
|
Uke 80
|
|
Prosentandel av deltakere som oppnår vektreduksjon på ≥ 10 %
Tidsramme: Uke 80
|
Uke 80
|
|
Prosentandel av deltakere som oppnår vektreduksjon på ≥ 15 %
Tidsramme: Uke 80
|
Uke 80
|
|
Prosentandel av deltakere som oppnår HbA1c ≤ 6,5 % og ≥ 10 % vektreduksjon
Tidsramme: Uke 80
|
Uke 80
|
|
Prosentvis endring fra baseline i triglyserider
Tidsramme: Uke 80
|
Uke 80
|
|
Prosentvis endring fra baseline i ikke-høydensitetslipoprotein (HDL) kolesterol
Tidsramme: Uke 80
|
Uke 80
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 18805
- J1I-MC-GZBZ (Annen identifikator: Eli Lilly and Company)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD-delingstidsramme
Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Tilgangskriterier for IPD-deling
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .